Patents Examined by Sagar Patel
  • Bicyclic compounds and methods of use
    Patent number: 10570147
    Abstract: The present invention provides compounds that modulate protein function, specifically phosphodiesterase 4 (PDE4). The invention provides methods of treating, ameliorating, and/or preventing diseases, disorders, and conditions associated with PDE4. Compositions, including in combination with other inflammatory mediators, are also provided.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: February 25, 2020
    Assignee: BioTheryX, Inc.
    Inventors: Robert Sullivan, Paul E. Erdman, Eduardo Torres, Leah Fung, Kyle W. H. Chan, Frank Mercurio
  • Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
    Patent number: 10570115
    Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 25, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Timothy Alcacio, Minson Baek, Peter Grootenhuis, Sara Sabina Hadida Ruah, Robert M. Hughes, Ali Keshavarz-Shokri, Rachel McAuley-Aoki, Jason McCartney, Mark Thomas Miller, Fredrick Van Goor, Beili Zhang, Corey Anderson, Thomas Cleveland, Bryan A. Frieman, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Vito Melillo, Fabrice Jean Denis Pierre, Andreas P. Termin, Johnny Uy, Jinglan Zhou, Alexander Russell Abela, Brett Bradley Busch, Prasuna Paraselli, David Andrew Siesel
  • Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
    Patent number: 10562859
    Abstract: Disclosed herein are compounds having the following structure useful as inhibitors of carbonic anhydrase IX (CAIX) and XII, and particularly useful for reducing or eliminating metastases see Formula (I).
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 18, 2020
    Assignee: SIGNALCHEM LIFESCIENCES CORPORATION
    Inventor: Zaihui Zhang
  • Cancer therapeutics
    Patent number: 10562890
    Abstract: This invention relates to compounds that bind to wild-type CBF? and inhibit CBF? binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBF? from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBF? in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: February 18, 2020
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: John H. Bushweller, Anuradha Illendula
  • Bis-diazeniumdiolate compounds as anti-cancer agents
    Patent number: 10556875
    Abstract: A series of double-component, bis O2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 11, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventor: Shengxi Chen
  • Acyl sulfonamide NaV1.7 inhibitors
    Patent number: 10550080
    Abstract: The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: February 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen
  • Malononitrile oxime ether compound and use thereof
    Patent number: 10544092
    Abstract: Disclosed is a malononitrile oxime ether compound having a novel structure as shown in the general formula I. Respective substituents in the general formula I as defined in the specification. The compound of the general formula I exhibits an excellent microbicidal activity, and can effectively prevent and treat plant diseases caused by bacteria and fungi. Also provided is a use of the compound of the general formula I as a microbicide in the agricultural and other fields.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 28, 2020
    Assignee: SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD.
    Inventors: Xueming Cheng, Lixin Zhang, Liang Chen, Qin Sun, Junli Liu, Zhinian Li, Jie Zhao, Jingbo Xu, Hongfei Wu
  • Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
    Patent number: 10544155
    Abstract: The present invention relates to spirocyclic quinolizine derivatives and pharmaceutically acceptable salts or prodrug thereof, compositions comprising at least one spirocyclic quinolizine derivative, and methods of using the spirocyclic quinolizine derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: January 28, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yonglian Zhang, Sherman T. Waddell, Tao Yu, John A. McCauley, Andrew Stamford
  • Method for preparing 3-((2S, 5S)-4-methylene-5-(3-oxopropyl)tetrahydrofurane-2-yl) propanol derivative, and intermediate therefor
    Patent number: 10538539
    Abstract: A method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative by a simple process with high yields, and an intermediate useful for the method.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: January 21, 2020
    Assignee: YONSUNG FINE CHEMICAL CO., LTD.
    Inventors: Hyun Ik Shin, Kee Young Lee, Changyoung Oh
  • Compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 10538497
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: January 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Purakkattle Biju, Yongqi Deng, Xavier Fradera, Liangqin Guo, Shuwen He, Joseph Kozlowski, Ravi Kurukulasuriya, Kun Liu, Meredeth Ann McGowan, Qinglin Pu, Nunzio Sciammetta, Hongjun Zhang, Hua Zhou
  • Histone deacetylase inhibitors
    Patent number: 10526346
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 7, 2020
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
    Patent number: 10526290
    Abstract: The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: January 7, 2020
    Assignee: SYNBIAS PHARMA AG
    Inventors: Helmut Schickaneder, Christian Schickaneder, Armin Buschauer, Stefan Huber, Michael Limmert, Günther Bernhardt, Mathias Lubbe, Harald Hofmeier
  • Nuclear transport modulators and uses thereof
    Patent number: 10526295
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: January 7, 2020
    Assignee: Karyopharm Therapeutics Inc.
    Inventor: Erkan Baloglu
  • Prodrugs of dithiol mucolytic agents
    Patent number: 10526283
    Abstract: Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 7, 2020
    Assignee: PARION SCIENCES, INC.
    Inventors: Michael Ross Johnson, William R. Thelin
  • Chalcone compounds
    Patent number: 10512631
    Abstract: This disclosure relates to the compounds of formula (I): [INSERT FORMULA], in which A and R1-R12 are defined in the Specification. The compounds of formula (I) have therapeutic effects, such as treating cancers.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 24, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Barbara Wegiel, Lijun Sun
  • Inhibitors of the renal outer medullary potassium channel
    Patent number: 10513518
    Abstract: The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 24, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Reynalda K. deJesus, Qinghong Fu, Jinlong Jiang, Haifeng Tang
  • Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
    Patent number: 10508115
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 17, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Sanjeev Gangwar, Yam B. Poudel, Prasanna Sivaprakasam
  • Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
    Patent number: 10487093
    Abstract: This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 26, 2019
    Assignee: Redx Pharma PLC
    Inventors: Ian Cooper, Amanda Lyons, David Orr, James Kirkham, Kevin Blades
  • Sortilin binding compounds, formulations, and uses thereof
    Patent number: 10478421
    Abstract: Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analogue thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: November 19, 2019
    Assignees: University of Florida, University of Rochester
    Inventors: Robert Pleasants Sparks, Wayne Charles Guida, Janet Lindsay DeHoff-Sparks
  • Compound, preparation method therefor, applications thereof, corresponding targeted drug delivery system, chemotherapy drugs, and treatment method
    Patent number: 10464885
    Abstract: The present invention relates to a compound and its preparation method and use and corresponding targeted drug delivery systems and chemotherapeutic drugs. The compound is a novel compound or a pharmaceutically acceptable salt thereof for treating small cell lung cancer, characterized in that, the compound has the general formula I, wherein R is acyloxy group. The present invention also relates to a preparation method of the compound, to use of the compound for the preparation of a chemotherapeutic drug for treating small cell lung cancer, to a targeted drug delivery system including the compound, and to a chemotherapeutic drug including the compound and for treating small cell lung cancer.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: November 5, 2019
    Assignee: BEIJING XINDE RUNXING TECHNOLOGY CO., LTD.
    Inventors: Xuechun Lu, Xiaohua Chi, Chengcheng Tang, Lei Shi